Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Emergent Biosolutions Inc Diversifies Its Revenue

TheMotleyFool

0 0

Emergent Biosolutions Inc Diversifies Its Revenue

One knock on Emergent Biosolutions (NYSE: EBS) has always been its dependence on anthrax vaccine BioThrax, but management made good on its promise to diversify, moving toward its goal of having $1 billion in revenue by 2020.

Metric

Q2 2017

Source: Fool.com